New placental proteins: chemistry, physiology and clinical use.
In the past decade, several new placental proteins have been isolated and studied. The 'pregnancy-specific' beta 1-glycoprotein (SP1) is a major placental product with unusual physicochemical properties that has been extensively investigated, but its biological function remains uncertain. Pregnancy-associated plasma protein A (PAPP-A), a glycoprotein of mol. wt 400,000, has effects in vitro on the coagulation and complement cascades, probably by its properties of protease inhibition. Placental protein 5 (PP5) may be involved in the coagulation and fibrinolytic systems, and in follicle maturation and semen liquefaction. 'Placental protein 12' (PP12) is not a product of the placenta at all; it appears to be produced in the female genital tract under the influence of progesterone and may also be produced by proliferating liver cells. Further study may reveal new roles for these placental proteins beyond their traditional roles as tumour markers.
D005260:Female; D006023:Glycoproteins; D006801:Humans; D018970:Insulin-Like Growth Factor Binding Protein 1; D018969:Insulin-Like Growth Factor Binding Proteins; D011247:Pregnancy; D011257:Pregnancy Proteins / Q000032:analysis / Q000302:isolation & purification* / Q000502:physiology; D011266:Pregnancy-Associated Plasma Protein-A / Q000032:analysis; D011268:Pregnancy-Specific beta 1-Glycoproteins / Q000032:analysis
D006023:Glycoproteins; C032231:IGFBP1 protein, human; D018970:Insulin-Like Growth Factor Binding Protein 1; D018969:Insulin-Like Growth Factor Binding Proteins; D011257:Pregnancy Proteins; D011268:Pregnancy-Specific beta 1-Glycoproteins; C021240:tissue-factor-pathway inhibitor 2; D011266:Pregnancy-Associated Plasma Protein-A